| Literature DB >> 31427302 |
Lloyd Tanner1, Joanna C Evans2,3, Ronnett Seldon2,3,4, Audrey Jordaan2,3, Digby F Warner2,3,5, Richard K Haynes6, Christopher J Parkinson7, Lubbe Wiesner8.
Abstract
Mycobacterium tuberculosis, the causative agent of tuberculosis, remains a leading infectious killer globally, demanding the urgent development of faster-acting drugs with novel mechanisms of action. Riminophenazines such as clofazimine are clinically efficacious against both drug-susceptible and drug-resistant strains of M. tuberculosis We determined the in vitro anti-M. tuberculosis activities, absorption, distribution, metabolism, and excretion properties, and in vivo mouse pharmacokinetics of a series of structurally related phenoxazines. One of these, PhX1, displayed promising drug-like properties and potent in vitro efficacy, supporting its further investigation in an M. tuberculosis-infected animal model.Entities:
Keywords: ADME; TB chemotherapy; pharmacokinetics; phenoxazines
Mesh:
Substances:
Year: 2019 PMID: 31427302 PMCID: PMC6811447 DOI: 10.1128/AAC.01010-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191